Safety and Efficacy of Inhaled XW001 (Interleukin 29 Analog for Nebulization) For Hospitalized COVID-19 Patients Requiring Oxygen Therapy: A Multiregional, Randomized, Double-blind, Placebo-controlled Study
Latest Information Update: 23 Aug 2023
At a glance
- Drugs XW 001 (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 respiratory infection
- Focus Adverse reactions
- Sponsors Sciwind Biosciences
- 17 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. (Difficulty in COVID-19 subject enrollmen)
- 22 Oct 2021 New trial record